Administrative Core

行政核心

基本信息

批准号：
7676462
负责人：
DAVID H WALKER
金额：
$ 71.89万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-15 至 2014-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7676462
关键词：
Academia Acellular Vaccines Adjuvant Alphavirus Animal Model Animal Welfare Animals Anthrax disease Antibodies Antigens Antiviral Agents Applied Research Area Arenavirus Arkansas Attenuated Attenuated Vaccines Bacillus anthracis spore Bacteria Basic Science Binding Sites Bioinformatics Biological Assay Biotechnology Brucella Vaccine Brucella melitensis Burkholderia mallei Capsid Caring Categories Cells Chemicals Chikungunya virus Chimera organism Chromatography Clinic Clinical Clinical Pathology Cloning Code Collaborations Collection Communicable Diseases Communities Complement Computational Biology Consult Core Facility Coupled Coxiella burnetii Cryptosporidium Culicidae Cyclic Peptides DNA Resequencing Data Data Analyses Data Set Databases Dengue Detection Developed Countries Developing Countries Development Diagnosis Diagnostic Diagnostic tests Diarrhea Disease Disulfides Drug Industry Emergency Situation Emerging Communicable Diseases Employment Encephalitis Viruses Endemic Flea-Borne Typhus Epidemic Epitopes Equilibrium Equine Encephalomyelitis Event Experimental Designs Family Filovirus Flavivirus Francisella tularensis Frankfurt-Marburg Syndrome Virus Funding Future Genes Genetic screening method Genomics Geographic Locations Germination Glanders Goals Grant Human Human Resources Immune Targeting Immunity In Vitro Individual Infection Infectious Agent Infectious Diseases Research Institution Intellectual Property Interdisciplinary Study International Aspects Internet Intestines Investigation Japanese Encephalitis Junin virus Knowledge Laboratories Lateral Laws Lead Leadership Leg Legal Legal patent Life Ligands Lipid A Lipopolysaccharides Literature Louisiana Measurement Medical Melioidosis Membrane Membrane Proteins Microarray Analysis Microencapsulations Microfluidics Mission Modeling Molecular Molecular Conformation Mutation Names National Institute of Allergy and Infectious Disease Natural History Nature New Mexico Nipah Virus Norovirus Nucleic Acids O Antigens Oklahoma Oligonucleotide Probes Open Reading Frames Organism Orthobunyavirus Pan Genus Parasites Participant Pathogenesis Pathway interactions Peptides Performance Pharmaceutical Preparations Phase Phase I Clinical Trials Policy Analysis Primates Prions Process Proteins Proteome Proteomics Protozoa Publications Q Fever Qualifying RNA Viruses Reagent Recombinant Proteins Regulation Research Research Activity Research Infrastructure Research Personnel Research Project Grants Research Training Resources Rickettsia Rift Valley Fever Rift Valley fever virus Rodent Role SARS coronavirus Safety Salmonella Sampling Scheme Science Scientist Services Site Slide Spottings Strategic Planning Structure Subunit Vaccines Sum T-Lymphocyte Tadpoles Techniques Technology Testing Texas Text Therapeutic Therapeutic Agents Time Toxin Training Translational Research Translations Tularemia Uncertainty Universities Vaccinated Vaccines Venezuelan Equine Encephalitis Virus Venezuelan Equine Encephalomyelitis Viral Virulence Virulence Factors Virus Virus Diseases Virus-like particle Walkers Work Yellow Fever aptamer bacterial genetics base biodefense biothreat capsule commercialization computer code cost crosslink design env Gene Products federal policy high throughput screening human subject immunogenic in vivo inhibitor/antagonist innovation instrumentation man member molecular recognition nanoparticle neglect new technology nonhuman primate novel novel strategies novel therapeutics optical sensor particle pathogen point of care point-of-care diagnostics programs receptor research and development research study response stem success sugar therapeutic vaccine tool vaccine development vaccine evaluation virus genetics

Academia Acellular Vaccines Adjuvant Alphavirus Animal Model Animal Welfare Animals Anthrax disease Antibodies Antigens Antiviral Agents Applied Research Area Arenavirus Arkansas Attenuated Attenuated Vaccines Bacillus anthracis spore Bacteria Basic Science Binding Sites Bioinformatics Biological Assay Biotechnology Brucella Vaccine Brucella melitensis Burkholderia mallei Capsid Caring Categories Cells Chemicals Chikungunya virus Chimera organism Chromatography Clinic Clinical Clinical Pathology Cloning Code Collaborations Collection Communicable Diseases Communities Complement Computational Biology Consult Core Facility Coupled Coxiella burnetii Cryptosporidium Culicidae Cyclic Peptides DNA Resequencing Data Data Analyses Data Set Databases Dengue Detection Developed Countries Developing Countries Development Diagnosis Diagnostic Diagnostic tests Diarrhea Disease Disulfides Drug Industry Emergency Situation Emerging Communicable Diseases Employment Encephalitis Viruses Endemic Flea-Borne Typhus Epidemic Epitopes Equilibrium Equine Encephalomyelitis Event Experimental Designs Family Filovirus Flavivirus Francisella tularensis Frankfurt-Marburg Syndrome Virus Funding Future Genes Genetic screening method Genomics Geographic Locations Germination Glanders Goals Grant Human Human Resources Immune Targeting Immunity In Vitro Individual Infection Infectious Agent Infectious Diseases Research Institution Intellectual Property Interdisciplinary Study International Aspects Internet Intestines Investigation Japanese Encephalitis Junin virus Knowledge Laboratories Lateral Laws Lead Leadership Leg Legal Legal patent Life Ligands Lipid A Lipopolysaccharides Literature Louisiana Measurement Medical Melioidosis Membrane Membrane Proteins Microarray Analysis Microencapsulations Microfluidics Mission Modeling Molecular Molecular Conformation Mutation Names National Institute of Allergy and Infectious Disease Natural History Nature New Mexico Nipah Virus Norovirus Nucleic Acids O Antigens Oklahoma Oligonucleotide Probes Open Reading Frames Organism Orthobunyavirus Pan Genus Parasites Participant Pathogenesis Pathway interactions Peptides Performance Pharmaceutical Preparations Phase Phase I Clinical Trials Policy Analysis Primates Prions Process Proteins Proteome Proteomics Protozoa Publications Q Fever Qualifying RNA Viruses Reagent Recombinant Proteins Regulation Research Research Activity Research Infrastructure Research Personnel Research Project Grants Research Training Resources Rickettsia Rift Valley Fever Rift Valley fever virus Rodent Role SARS coronavirus Safety Salmonella Sampling Scheme Science Scientist Services Site Slide Spottings Strategic Planning Structure Subunit Vaccines Sum T-Lymphocyte Tadpoles Techniques Technology Testing Texas Text Therapeutic Therapeutic Agents Time Toxin Training Translational Research Translations Tularemia Uncertainty Universities Vaccinated Vaccines Venezuelan Equine Encephalitis Virus Venezuelan Equine Encephalomyelitis Viral Virulence Virulence Factors Virus Virus Diseases Virus-like particle Walkers Work Yellow Fever aptamer bacterial genetics base biodefense biothreat capsule commercialization computer code cost crosslink design env Gene Products federal policy high throughput screening human subject immunogenic in vivo inhibitor/antagonist innovation instrumentation man member molecular recognition nanoparticle neglect new technology nonhuman primate novel novel strategies novel therapeutics optical sensor particle pathogen point of care point-of-care diagnostics programs receptor research and development research study response stem success sugar therapeutic vaccine tool vaccine development vaccine evaluation virus genetics

展开

项目摘要

The Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (WRCE) is located in DHHS Region VI, including Texas, New Mexico, Oklahoma, Arkansas, and Louisiana. Dr. David H. Walker is the PI and director for the WRCE. The University of Texas Medical Branch at Galveston (UTMB) is the lead institution. Academic institutions within the WRCE possess remarkable depth and breadth of scientific expertise related to Category A, B, and C priority pathogens and emerging and re-emerging infectious disease agents. From the very beginning, the WRCE leadership has strived to access this expertise and to make the WRCE a genuine cross-institutional Center involving all member states, not just in name or by concentrating projects at a few universities. The fact that over 100 project leaders at 34 different institutions have received funding from the WRCE is a testament to the plural nature of the WRCE program. The sense of collaboration and spirit of cooperation among investigators from traditionally competing institutions was previously unimaginable prior to the establishment of the WRCE in 2003 under Dr. Walker's guidance and strong leadership. The activities of the WRCE are firmly centered on supporting NIAID's Biodefense Research Agenda, and this application reaffirms our commitment to this strategy. The WRCE program is a success, as evaluated by a number of parameters that consider the whole Center as contributing more than the sum of its individual member institutions and investigators. In the assessment of the national RCE Program, several individual Center measurements were provided. They revealed that the WRCE ranked first in the number of organisms studied, total number of projects, number of Pis, additional non- RCE funding stemming from WRCE research, and number of patent applications as compared to the other individual Centers [1]. Our publication rate is also the one of the highest of the Centers. Since the WRCE was originally funded in September 2003, excellent progress has been made toward producing promising leads for biodefense countermeasures. WRCE translational research resulted in a wealth of significant basic biologic research as well, and the two are not mutually exclusive. Publications from WRCE researchers have resulted in new knowledge about the role of capsule in dissemination of inhalational anthrax, anthrax spore germination, rickettsial genes involved in phagosomal escape, the role of nonstructural genes in the replication of Rift Valley fever virus, the genetics of Nipah virus, and Venezuelan equine encephalitis virus host cell entry mechanisms, to name but a few. Additionally, the well characterized animal models developed by the WRCE Small Animal Core, Nonhuman Primate Core, and select project leaders all contributed knowledge about the natural history and pathogenesis of infections, and these investigations are an essential component for supporting applied research. The original WRCE application in 2003 had a very broad thematic structure in the strategic plan. The focus of the WRCE leadership was to fund the very best science and to take full advantage of the diversity of infectious disease and microbiologic expertise in our region. To date, the WRCE has funded 72 research projects and ten cores, including two trans-RCE cores that resided in our region. This work involved 30 different agents, including nine bacteria, 18 viruses, one protozoan, and two toxins. Given the yield in WRCE patents and publications, the institutions and investigators receiving funding, and projects advancing toward tangible products, this strategy served us very well during the first grant cycle. As the WRCE program matured, four themes emerged that logically encompassed the most productive projects that were likely to lead to biodefense countermeasures. The four themes are as follows: 1. Development of Therapeutic Agents for RNA Viruses 2. Platforms for Multiplexed Diagnostics for Category A-C Agents and Emerging Agents 3. Vaccine Development for Arboviral and Emerging Viral Diseases 4. Vaccine Development for Diseases Caused by Intracellular Bacteria These themes will no doubt serve to help us converge and synergize as we embark on the next leg of our research journey within the WRCE

西方地区的生物形式和新兴传染病研究中心（WRCE）位于DHHS地区VI，包括德克萨斯州，新墨西哥州，俄克拉荷马州，阿肯色州和路易斯安那州。博士大卫·H·沃克（David H. Walker）是WRCE的PI和导演。德克萨斯大学医学分支机构（UTMB）是主要机构。 WRCE中的学术机构具有显着的深度和广度与A，B和C优先病原体以及新兴和重新出现有关的科学专业知识传染病药物。从一开始，WRCE领导力一直努力获得这一专业知识并使WRCE成为一个真正涉及所有成员国的真正跨机构中心在几所大学集中项目。 34个不同机构的100多名项目负责人这一事实从WRCE获得资金证明了WRCE计划的复数性质。感官传统竞争机构的调查员之间的合作和合作精神是在2003年在Walker博士的指导下建立WRCE之前，以前难以想象强大的领导。 WRCE的活动牢固地集中在支持NIAID的生物形式研究上议程，该应用程序重申了我们对该策略的承诺。 WRCE程序是成功的，如许多考虑整个中心的参数所评估作为其各个会员机构和调查人员的总和还多。在评估中国家RCE计划，提供了几项单独的中心测量。他们透露了 WRCE在研究的生物数量，项目总数，PIS数量，其他非 - 与其他相比个别中心[1]。我们的出版率也是最高中心之一。由于WRCE是最初由2003年9月资助，在为产生有希望的线索的领先方面取得了良好的进步生物反应对策。 WRCE翻译研究带来了大量重要的基本生物学研究也不是相互排斥的。 WRCE研究人员的出版物已导致关于胶囊在传播吸入炭疽中的作用的新知识，炭疽孢子发芽，立克基因参与吞噬体逃生，非结构基因在复制中的作用 Rift Valley Fever病毒，Nipah病毒的遗传学和委内瑞拉马脑炎病毒宿主细胞进入机制，仅举几例。此外，WRCE开发的良好特征动物模型小型动物核心，非人类灵长类动物核心和精选项目领导者都贡献了有关感染的自然病史和发病机理，这些研究是支持应用研究。 2003年最初的WRCE应用程序在战略计划中具有非常广泛的主题结构。这 WRCE领导的重点是为最好的科学提供资金，并充分利用多样性我们地区的传染病和微生物学专业知识。迄今为止，WRCE资助了72项研究项目和十个核心，包括我们地区居住的两个透射核心。这项工作涉及30 不同的药物，包括九种细菌，18种病毒，一种原生动物和两种毒素。鉴于WRCE的产量专利和出版物，机构和调查人员获得资金，以及前进的项目有形产品，这种策略在第一个赠款周期为我们提供了很好的服务。作为WRCE程序成熟的，四个主题出现了，从逻辑上涵盖了最有生产力的项目导致生物反应对策。这四个主题如下： 1。开发RNA病毒的治疗剂 2。用于A-C类代理和新兴代理的多路复用诊断平台 3。藻类病毒和新兴病毒疾病的疫苗开发 4。由细胞内细菌引起的疾病疫苗发育当我们踏上我们的下一个工作时，这些主题无疑会帮助我们融合和协同作用 WRCE内的研究旅程